IPHA

Innate Pharma

IPHA.US innate-pharma.com + Research + Basket
Employees 120
Phone 33 4 30 30 30 30
Fiscal year end December
IPO Oct 17, 2019
Address 117, Avenue de Luminy, Marseille, France, 13009
1.50
-0.02 (-1.32%)
USD · NASDAQ
52-week range
1.17
2.71
Trading at 21% of the 52-week range
Market Cap
169.78M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.49
Div. Yield
N/A
% Institutions
0.350%
% Insiders
1.40%

1 Year

-27.5%

3 Year

-36.3%

10 Year

-75.2%
Description

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Actions

Add an action for IPHA.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Jonathan E. Dickinson B.Sc., M.B.A. CEO & Director 1968
Mr. Yannis Morel Ph.D. Executive VP & COO 1973
Dr. François Romagné Ph.D. Founder 1964
Dr. Marc Bonneville Ph.D. Founder 1960
Mr. Jean Jacques Fournié Ph.D. Founder NA
Mr. Alessandro Moretta M.D., Ph.D. Founder NA
Mr. Frederic Lombard M.B.A. Senior VP & CFO 1975
Ms. Stephanie Cornen Vice President of Investor Relations, Communication & Commercial Strategy 1987
Ms. Odile Belzunce VP, Chief of Compliance & Operations Officer and Interim Head of HR 1980
Ms. Claire de Saint Blanquat VP of Legal & Corporate Affairs and Secretary of the Supervisory Board 1973

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Lion Point Capital, LP 81.15K Jun 30, 2026 0.07% $0.71 0.00%
Morgan Stanley - Brokerage Accounts 43.52K Jun 30, 2026 0.04% $0.00 0.00%
SmartHarvest Portfolios, LLC 23.75K Jun 30, 2026 0.02% $0.01 0.00%
XTX Topco Ltd 15.13K Jun 30, 2026 0.01% $0.00 0.00%
Citadel Advisors Llc 12.44K Jun 30, 2026 0.01% $0.00 0.00%
Jane Street Group LLC 10.31K Jun 30, 2026 0.01% $0.00 -76.23%
Rhumbline Advisers 4.72K Jun 30, 2026 0.00% $0.00 -0.32%
UBS Group AG 1.36K Jun 30, 2026 0.00% $0.00 58.30%
GAMMA Investing LLC 9.00 Jun 30, 2026 0.00% $0.00 -96.25%
Caitong International Asset Management Co., Limited. 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
OLD MISSION CAPITAL LLC. 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Sageview Advisory Group LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%
Barclays PLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Millennium Management LLC 0.00 Jun 30, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Telescope Biotech Fund A FIL 249.31K 0.22% ▲ 23.92% Sep 30, 2026
2 Generali France PME ETI A 125.98K 0.11% ▲ 0.00% Jul 31, 2026

Financial Highlights

▼
Market Cap: $169.78M
EBITDA: $-46.96M
Book Value: $-0.49
Earnings/Share: $-0.63
Profit Margin: 0.00%
Operating Margin: -335.71%
ROA (TTM): -46.60%
ROE (TTM): -271.37%
Revenue (TTM): $9.81M
Revenue/Share (TTM): $0.11
Earnings Growth (YOY): -74.70%
Revenue Growth (YOY): 16.50%

Valuation Metrics

Enterprise Value: $169.16M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 111.70M
Shares Float: 68.87M
% Insiders: 1.40%
% Institutions: 0.350%
Short % Float: 0.11%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$2.79M
Gross Profit
subtotal
$2.79M
SG&A
adjust
$-11.00M
R&D
adjust
$-43.62M
Other Operating Expense
adjust
$-1.59M
Operating Income
subtotal
$-53.43M
Other / Non-Operating Items
adjust
$4.25M
Net Income
subtotal
$-49.18M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IPHA.US!